Research and development daily Rongchang bio-anti-HER2 antibody association drugs to be incorporated into the breakthrough treatment...

2020.12.17 Research and Development NEWS: Novo Nordis directly launched the 3700-person PHASE IIIa trial; Hengrui Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical reached the main research endpoint; Novarce's potential first-in-class oral supplement pathline inhibitor was identified by FDA breakthrough therapy; Nanjing Jianyou, Beijing Ted "Benzene Shun Aku ammonium injection" is about to be approved for listing ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) Drug Research and Development improves AD patient cognitive indicators Innovative oral therapy reaches the primary clinical endpoint of phase 2b/3 today, AB Science announced that it has reached its intended primary endpoint in the 2b/3 clinical trial of the oral therapy masitinib in the treatment of patients with mild and moderate Alzheimer's disease.
significantly improved changes in memory and cognitive indicators compared to placebos.
somaglutides to treat Alzheimer's disease! Novo Nordisk directly launched the 3,700-person Phase IIIa trial on the 16th, Novo Nordisk announced that it will launch a Phase III research project on the treatment of Alzheimer's disease with oral Smeglutide (Somaglutide).
's decision was made after assessing preclinical animal model data, real-world research data, and post-mortem results from large cardiovascular outcome studies, and was discussed with regulators.
Hengrui Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical end of the main study 16, Hengrui Pharmaceutical announced that innovative drug injection carelli pearl monoanti (Erika) in two phase 3 clinical studies reached the main research endpoint: one for combined yew alcohol and cisplatin for advanced esophageal cancer first-line treatment;
(The Drug Approval) Novart's potential first-in-class oral supplement pathrapy inhibitor was recognized by the FDA today, Novardo announced that the FDA has awarded it a breakthrough therapy for the developmental therapy iptacopan (LNP023) for the treatment of bursts of sleep hemoglobinuria.
iptacopan was also identified as a rare pediatric disease to treat C3 renal ocytic disease.
Iptacopan is a potential "first-in-class" oral-specific alternative to complement pathway factor B inhibitors.
Rongchang bio-anti-HER2 antibody combination drugs are intended to be included in the breakthrough treatment varieties today, CDE official website of the latest publicity, Rongchang biological submission of "injection recombinant humanized anti-HER2 monoantigenic-MMAE coupled agent" to be included in the breakthrough treatment varieties, the proposed adaptation for the past after the failure of chemotherapy progress of HER2 over-expression of local late stage or metastatic urethra cancer patients.
JAK Inhibitor was eligible for FDA Orphan Drug Today, Zee-Pharma issued a press release in which the company was awarded orphan drug by the FDA for the treatment of bone marrow fibrosis by developing the innovative chemical Jacphedrini tablet hydrochloric acid.
National Jianyou, Beijing Ted "Benzene Shun Aquku ammonium injection" will be approved for listing today, Nanjing Jianyou, Beijing Ted according to the 4 categories of registered declaration of benzene Shun Aquku ammonium injection is in the "in the approval" stage, is expected to be approved by the State Drug Administration in the near future, becoming the first two enterprises of the variety through consistent evaluation.
Enhua Pharmaceuticals", the first to pass a consistent evaluation today, Enhua Pharmaceuticals announced that Mida zolun injection through a consistent evaluation application, becoming the first drug through generic quality and efficacy consistency evaluation manufacturers.
Osteoporosis new drug Aedes aeoporosis softgel was approved for listing in China on the 16th, NMPA announced that the new drug Edicol softgel (eldecalcitol, the research and development code-name ED-71) developed by Roche's Japanese Chinese and foreign pharmaceutical co., Ltd. has been officially approved for listing in China.
, an active vitamin D3 derivative used to treat osteoporosis, according to public information released last week.
risk of death is reduced by 24% compared to curly bead monoantial resistance! FDA approved Fc retrofit HER2 monoantigen market 16, MacroGenics announced that the FDA approved Margenza (margetuximab-cmkb) listing application, combined chemotherapy to treat adult metastasis HER2-positive breast cancer, these patients have previously received at least two or more anti-HER2 treatments, at least one of which is used for metastasis breast cancer.
Agen submitted a listing application for KRAS inhibitor AMG 510 on the 16th, Amgen announced that it had submitted to the FDA a listing application for KRASG12C inhibitor soorasib (AMG 510) for treatment of locally advanced or metastassic non-small cell lung cancer (NSCLC) with KRASG12C mutation that has received at least one systematic treatment in the past.
Qilu pharmaceutical Malay acid Isola tablets through the consistent evaluation of supplementary applications 16, the Official Website of the State Drug Administration shows that Qilu Pharmaceuticals' Malay acid Isola tablets through the consistent evaluation of supplementary applications.
Isola tablets for gastric mucous membrane protection agent, Qilu Pharmaceuticals for the first evaluation of the variety of enterprises.
, Qilu Pharmaceuticals has 45 varieties have been evaluated.
and Nord once a week subsuplision injection weight loss new drugs approved clinically in China on the 16th, the Drug Review Center (CDE) latest publicity Novo Nordiak AM833 (NNC0174-0833 injection) obtained the default license for clinical trials, intended to be developed for weight management in obese/overweight patients.
the first in China! Health Yuan "omega-3 fish oil / long-chain fat emulsion" was approved for listing on the 16th, health yuan announcement announced that its wholly-owned subsidiary Shenzhen Waterfront Pharmaceutical Co., Ltd. received the State Drug Administration approved the issuance of omega-3 fish oil / long-chain fat emulsion "drug registration certificate."
, health yuan has invested directly in the research and development of omega-3 fish oil/long-chain fat emulsions at a cost of about RMB 34.9356 million.
45% full remission rate for melanoma patients! On the 15th, IO Biotech announced that the FDA has awarded it the status of a breakthrough therapy for the development of a combination of tumor vaccines IO102 and IO103 against PD-1 monoantial therapy for non-removable/metastasis melanoma.
Nanjing Zhengtianqing new product Omeshatan ammonia chloride tablets listed recently, Nanjing Zhengtian qing cardiovascular key products Tianshuping® (Omeshatan ammonia chloride tablets) access to the State Drug Administration's pharmaceutical production batch, the product belongs to the chemical drug category 4, as well as through the quality and efficacy of consistent evaluation.
Huiyu pharmaceutical imitation 4 types of yew alcohol injection into the administrative approval stage recently, Huiyu pharmaceutical according to the imitation of 4 types of reported yew alcohol injection into the administrative approval stage, is expected to be approved recently and as reviewed.
Yew alcohol injection is a plant-based anti-tumor drug for ovarian and breast cancer and non-small cell lung cancer (NSCLC) first- and second-line treatment, for head and neck cancer, esophageal cancer, spermogen cell tumor, recurrence of non-Hokin's lymphoma and so on have a certain effect.
Xinly, sgk1, a new target for Alzheimer's disease, researchers have found that inhibiting certain enzymes associated with abnormal gene transcription can restore memory loss associated with Alzheimer's disease, a finding that offers hope for the development of a new treatment for Alzheimer's disease.
BMJ: Nearly a quarter of the world's population will not have access to the new crown vaccine until 2022, according to a new study published in the British Medical Journal.
at Johns Hopkins University's Bloomberg School of Public Health say high-income countries already have billions of doses of vaccine in stock, meaning access to vaccines is precarious in low- and middle-income countries.
。